UBS ASSET MANAGEMENT AMERICAS LLC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$907,105
-51.0%
44,0770.0%0.00%
-100.0%
Q2 2023$1,849,4700.0%44,0770.0%0.00%0.0%
Q1 2023$1,849,470
+15.2%
44,077
+4.7%
0.00%0.0%
Q4 2022$1,605,389
-99.9%
42,092
+5.7%
0.00%0.0%
Q3 2022$1,558,724,000
-7.3%
39,804
-23.6%
0.00%0.0%
Q2 2022$1,681,764,000
-31.5%
52,067
-29.8%
0.00%0.0%
Q1 2022$2,453,405,000
-63.4%
74,121
-52.9%
0.00%
-66.7%
Q4 2021$6,697,371,000
-4.4%
157,437
-0.4%
0.00%0.0%
Q3 2021$7,006,830,000
-21.8%
158,132
+0.2%
0.00%
-25.0%
Q2 2021$8,961,096,000
-39.4%
157,738
-20.2%
0.00%
-42.9%
Q1 2021$14,792,906,000
-58.2%
197,634
-51.7%
0.01%
-58.8%
Q4 2020$35,365,287,000
+29.9%
408,800
-8.2%
0.02%
+13.3%
Q3 2020$27,221,319,000
+48.5%
445,375
+1.0%
0.02%
+36.4%
Q2 2020$18,330,376,000
+147.4%
440,846
+70.9%
0.01%
+120.0%
Q1 2020$7,408,037,000
-63.4%
257,940
-7.9%
0.01%
-58.3%
Q4 2019$20,217,460,000
-21.3%
280,059
+52.9%
0.01%
-29.4%
Q3 2019$25,701,829,000
-36.8%
183,205
-17.6%
0.02%
-41.4%
Q2 2019$40,692,668,000
+26.9%
222,255
+10.2%
0.03%
+20.8%
Q1 2019$32,073,706,000
+78.7%
201,658
+7.6%
0.02%
+60.0%
Q4 2018$17,947,023,000
-29.9%
187,358
+3.4%
0.02%
-21.1%
Q3 2018$25,584,047,000
-7.6%
181,126
+2.4%
0.02%
-9.5%
Q2 2018$27,690,313,000
-1.4%
176,901
+1.4%
0.02%
-4.5%
Q1 2018$28,093,347,000
-2.9%
174,417
-0.7%
0.02%
-12.0%
Q4 2017$28,928,018,000
+98.4%
175,630
-25.0%
0.02%
+92.3%
Q3 2017$14,579,820,000
-18.2%
234,026
+4.6%
0.01%
-23.5%
Q2 2017$17,818,893,000
+7.6%
223,743
-4.0%
0.02%0.0%
Q1 2017$16,565,138,000
+84771.1%
233,082
-39.0%
0.02%
-22.7%
Q4 2016$19,518,000
+8.6%
382,249
-2.1%
0.02%
+15.8%
Q3 2016$17,978,000
+80.2%
390,406
+17.9%
0.02%
+72.7%
Q2 2016$9,974,000
+249.6%
331,056
+272.0%
0.01%
+266.7%
Q1 2016$2,853,000
-47.4%
88,992
-4.3%
0.00%
-50.0%
Q4 2015$5,422,000
+146.0%
92,991
+78.5%
0.01%
+200.0%
Q3 2015$2,204,000
-41.0%
52,087
+1.8%
0.00%
-50.0%
Q2 2015$3,736,000
+54.6%
51,171
+6.4%
0.00%
+100.0%
Q1 2015$2,416,000
+33.9%
48,100
-2.4%
0.00%0.0%
Q4 2014$1,804,000
+52.4%
49,300
+31.1%
0.00%
+100.0%
Q3 2014$1,184,00037,6000.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Finepoint Capital LP 475,600$15,362,0005.31%
Integral Health Asset Management, LLC 412,257$13,316,0002.74%
Palo Alto Investors LP 851,409$27,501,0002.40%
Boxer Capital, LLC 1,094,000$35,336,0002.24%
DAFNA Capital Management LLC 180,306$5,824,0001.59%
Ikarian Capital, LLC 250,000$8,075,0001.47%
Bellevue Group AG 2,973,178$96,034,0001.36%
SECTOR GAMMA AS 118,476$3,827,0000.86%
Artal Group S.A. 450,000$14,535,0000.78%
Diametric Capital, LP 19,393$626,0000.46%
View complete list of SAGE THERAPEUTICS INC shareholders